🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
Eligible participants with newly diagnosed myeloma who are not considered e...
Status
Recruiting
Location
Gundersen Lutheran
Start Date
2026-09
Trial ID
NCT07285239
Multiple myeloma (MM) is an incurable malignancy and accounts for 1 percent...
Status
Completed
Location
GSK Investigational Site
Start Date
2018-06-18
Trial ID
NCT03525678
Treatments Being Tested
This is a phase I/II, single arm, open label, two-part study that will asse...
Status
Completed
Location
GSK Investigational Site
Start Date
2019-03-14
Trial ID
NCT03848845
Treatments Being Tested
This phase I/II trial tests the safety, side effects, best dose, and effect...
Status
Recruiting
Location
Mary Greeley Medical Center
Start Date
2025-04-23
Trial ID
NCT06232044
This study will evaluate the efficacy and safety of belantamab mafodotin in...
Status
Active Not Recruiting
Location
GSK Investigational Site
Start Date
2020-10-01
Trial ID
NCT04484623
Treatments Being Tested
The purpose of this study is to compare the efficacy of talquetamab versus ...
Status
Withdrawn
Location
University of Arkansas for Medical Sciences
Start Date
2022-10-20
Trial ID
NCT05461209
Treatments Being Tested
Evaluate the efficacy and safety of Belantamab Mafodotin, cyclophosphamide,...
Status
Terminated
Location
University of Maryland
Start Date
2021-12-03
Trial ID
NCT04896658
Treatments Being Tested
This study will independently assess the efficacy and safety of 11 combinat...
Status
Recruiting
Location
Banner MD Anderson Cancer Center
Start Date
2015-10
Trial ID
NCT02343042
The purpose of this umbrella study is to evaluate isatuximab when combined ...
Status
Recruiting
Location
Winship Cancer Institute of Emory University- Site Number : 8400010
Start Date
2021-01-25
Trial ID
NCT04643002
Belantamab mafodotin (GSK2857916) is a first in class, antibody dependent c...
Status
Completed
Location
GSK Investigational Site
Start Date
2019-03-14
Trial ID
NCT03828292
Treatments Being Tested